Researchers say semaglutide significantly reduced liver scarring in patients with advanced fatty liver disease, offering new hope for millions worldwide.
A widely prescribed diabetes and weight-loss medication may soon become a breakthrough treatment for advanced fatty liver disease, according to new international research published in The Lancet Gastroenterology & Hepatology.
The findings suggest that semaglutide, a GLP-1 receptor agonist commonly used to manage type 2 diabetes and obesity, could help reduce liver scarring in patients with advanced metabolic dysfunction-associated steatohepatitis (MASH)—a severe form of fatty liver disease that can progress to cirrhosis, liver failure, and the need for a liver transplant.
Fatty liver disease is one of the fastest-growing chronic health conditions worldwide, driven largely by rising rates of obesity, overweight, and type 2 diabetes.
When excess fat builds up in the liver, it can trigger chronic inflammation known as MASH. Over time, this inflammation causes fibrosis, or permanent liver scarring, which can eventually develop into cirrhosis and significantly increase the risk of liver failure.
Despite the growing number of patients affected, treatment options for advanced MASH remain limited. Doctors have primarily relied on weight loss, healthy eating, and regular exercise because few medications have demonstrated meaningful success in reversing liver damage.
The original study evaluated a combination of semaglutide and an experimental metabolic drug called zalfermin.
Although the combination therapy did not significantly outperform the placebo, patients who received semaglutide alone experienced notable improvements in liver fibrosis without worsening the underlying inflammation responsible for continued liver damage.
Researchers observed these benefits even among participants with more advanced stages of the disease.
The study also found that modern blood tests and advanced imaging scans successfully monitored patients’ progress during treatment.
If confirmed in future studies, these non-invasive monitoring techniques could reduce the need for painful and costly liver biopsies, which are currently considered the standard method for evaluating liver damage.
While the results are encouraging, researchers caution that larger Phase 3 clinical trials are still required to determine whether semaglutide can prevent liver failure, reduce the need for transplantation, and improve long-term survival.
However, because semaglutide already has an established safety profile as an approved treatment for diabetes and obesity, experts believe its path toward wider use in liver disease treatment could be faster than that of entirely new medications.
The findings offer renewed optimism for millions of people living with advanced fatty liver disease, a condition that has long lacked effective medical therapies.
